Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Applications for liquid biopsy in urothelial carcinoma

Gillian Vandekerkhove • 15 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer

Gillian Vandekerkhove, PhD, Vancouver Prostate Centre, Vancouver, Canada, discusses the applications for liquid biopsy in urothelial carcinoma. This includes plasma circulating tumour DNA (ctDNA) and urine tumour DNA for use in screening, diagnosis and various treatment stages. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gillian Vandekerkhove

Applications for ctDNA in guiding treatment of urothelial carcinoma
0:42
Applications for ctDNA in guiding treatment of urothelial carcinoma
Gillian Vandekerkhove • 15 Feb 2025
Implementing liquid biopsy in multiple aspects of urothelial carcinoma
0:56
Implementing liquid biopsy in multiple aspects of urothelial carcinoma
Gillian Vandekerkhove • 15 Feb 2025
The future of liquid biopsy beyond non-genetic readouts in bladder cancer
0:49
The future of liquid biopsy beyond non-genetic readouts in bladder cancer
Gillian Vandekerkhove • 15 Feb 2025

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals